Credit Suisse’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Credit Suisse’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,700	Closed	-$871K	–	4389
2015 Q3	$871K	Hold	2,700	–	–	﹤0.01%	2934
2015 Q2	$1.08M	Hold	2,700	–	–	﹤0.01%	3113
2015 Q1	$1.33M	Buy	+2,700	New	+$1.05M	﹤0.01%	2742

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Credit Suisse's LUMO Position: Q2 2019 in Review

Credit Suisse sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2019, closing a stake of 1,681 shares — an estimated $29K sold.

Credit Suisse first reported a position in LUMO in Q2 2013 and held it in 23 quarters. The position peaked at $2.71M in Q2 2015. 68 funds tracked by Wall St. Rank hold LUMO as of Q2 2019.

Credit Suisse reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Credit Suisse sold 1,681 Lumos Pharma, Inc. Common Stock shares in Q2 2019, an estimated $29K.
Credit Suisse first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 23 quarters.
Credit Suisse's Lumos Pharma, Inc. Common Stock position peaked at $2.71M in Q2 2015.
68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.